Worldwide rates of either<unk> V-1 and/or<unk> V-2 are between 60 and 95% in adults.<unk> V-1 is more common than<unk> V-2, with rates of both increasing as people age.<unk> V-1 rates are between 70% and 80% in populations of low socioeconomic status and 40% to 60% in populations of improved socioeconomic status. An estimated 536 million people or 16% of the population worldwide were infected with<unk> V-2 as of 2003 with greater rates among women and in those in the developing world. Rates of infection are determined by the presence of antibodies against either viral species. In the US, 58% of the population is infected with<unk> V-1 and 16% are infected with<unk> V-2. Among those<unk> V-2-seropositive, only 19% were aware they were infected. During 2005–2008, the prevalence of<unk> V-2 was 39% in blacks and 21% in women. The annual incidence in Canada of genital<unk>  due to<unk> V-1 and<unk> V-2 infection is not known (for a review of<unk> V-1/HSV-2 prevalence and incidence studies worldwide, see Smith and Robinson 2002). As many as one in seven Canadians aged 14 to 59 may be infected with<unk>  type 2 virus and more than 90 per cent of them may be unaware of their status, a new study suggests. In the United States, it is estimated that about 1,640,000<unk> V-2 seroconversions occur yearly (730,000 men and 910,000 women, or 8.4 per 1,000 persons). In British Columbia in 1999, the seroprevalence of<unk> V-2 antibody in leftover serum submitted for antenatal testing revealed a prevalence of 17%, ranging from 7% in women 15–19 years old to 28% in those 40–44 years. In Norway, a study published in 2000 found that up to 70–90% of genital initial infections were due to<unk> V-1. In Nova Scotia, 58% of 1,790<unk> V isolates from genital lesion cultures in women were<unk> V-1; in men, 37% of 468 isolates were<unk> V-1.
Herpes simplex
Shingles
Lentigo simplex
Molluscum contagiosum
Herpes labialis
Herpes gladiatorum
Smallpox
Cowpox